OPPENHEIMER & CO INC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 144 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2016. The put-call ratio across all filers is 0.75 and the average weighting 0.7%.

Quarter-by-quarter ownership
OPPENHEIMER & CO INC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2018$3,000
-72.7%
16,735
-26.4%
0.00%
Q3 2018$11,000
-42.1%
22,735
-36.7%
0.00%
-100.0%
Q2 2018$19,000
-87.5%
35,935
-44.9%
0.00%
-75.0%
Q1 2018$152,000
-19.1%
65,270
-0.9%
0.00%
-20.0%
Q4 2017$188,000
+9.3%
65,870
+9.8%
0.01%0.0%
Q3 2017$172,000
-27.4%
59,995
-37.5%
0.01%
-28.6%
Q2 2017$237,000
-34.9%
95,946
-4.9%
0.01%
-30.0%
Q1 2017$364,000
-12.7%
100,871
-14.2%
0.01%
-16.7%
Q4 2016$417,000
-24.7%
117,580
-14.2%
0.01%
-25.0%
Q3 2016$554,000
-25.0%
137,087
-18.6%
0.02%
-27.3%
Q2 2016$739,000
-2.5%
168,358
-16.0%
0.02%
-4.3%
Q1 2016$758,000
-76.5%
200,442
-2.7%
0.02%
-76.0%
Q4 2015$3,231,000
+74.3%
206,062
+17.2%
0.10%
+71.4%
Q3 2015$1,854,000
-57.2%
175,864
+2.4%
0.06%
-53.3%
Q2 2015$4,331,000
-16.2%
171,728
-7.4%
0.12%
-14.9%
Q1 2015$5,170,000
+36.3%
185,477
-10.8%
0.14%
+29.4%
Q4 2014$3,793,000
+16.4%
207,858
-17.3%
0.11%
+12.4%
Q3 2014$3,258,000
-14.3%
251,382
+7.9%
0.10%
-14.9%
Q2 2014$3,803,000
+14.5%
233,012
+24.0%
0.11%
+14.0%
Q1 2014$3,322,000
+27.8%
187,981
+75.2%
0.10%
+20.5%
Q4 2013$2,599,000
-32.1%
107,318
-0.7%
0.08%
-38.5%
Q3 2013$3,829,000
+106.2%
108,076
-9.2%
0.14%
+87.5%
Q2 2013$1,857,000118,9790.07%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q4 2016
NameSharesValueWeighting ↓
KLP Enterprises, LLC 6,865,006$24,302,000100.00%
TSP Capital Management Group, LLC 886,398$3,138,0001.60%
Marcus Capital, LLC 109,950$389,0000.42%
RTW INVESTMENTS, LP 239,662$848,0000.32%
COLUMBIA WANGER ASSET MANAGEMENT LLC 6,195,855$21,933,0000.31%
Benchmark Capital Advisors 66,800$236,0000.20%
Bellevue Group AG 160,000$566,0000.12%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 632,944$2,241,0000.09%
PDT Partners, LLC 369,300$1,307,0000.09%
Vident Investment Advisory, LLC 196,715$696,0000.08%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders